TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
May 01, 2017 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
TESARO Initiates Registrational Development Program for Anti-PD-1 Antibody TSR-042
April 27, 2017 08:15 ET
|
TESARO, Inc.
TSR-042 is the first TESARO immuno-oncology candidate to enter a registration programOngoing clinical trial expanded to enroll patients with endometrial cancerPatient-centric administration...
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET
|
TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO to Announce First-Quarter 2017 Financial Results on May 9, 2017
April 25, 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., April 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first-quarter 2017 financial results on Tuesday, May 9, 2017, after the close of the U.S. financial...
TESARO Announces Availability of Zejula™ (Niraparib) for Patients With Recurrent Ovarian Cancer in the U.S.
April 19, 2017 16:15 ET
|
TESARO, Inc.
ZEJULA is the first and only PARP inhibitor to be approved for the maintenance treatment of women with recurrent ovarian cancerZEJULA is the only PARP inhibitor that has demonstrated a clinically...
Tesaro Wins Awards for Clinical Development Team of the Year and Clinical Partnership of the Year
April 07, 2017 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., April 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, has been recognized with two Clinical and Research Excellence (CARE)...
TESARO Announces Expanded Development Program for Niraparib Focused on the Treatment of Front-Line Metastatic Ovarian and Lung Cancers and Metastatic Breast Cancer
March 27, 2017 15:45 ET
|
TESARO, Inc.
Expanded niraparib ovarian cancer program intended to potentially transform the treatment of front-line ovarian cancerNew breast cancer clinical program for niraparib to address greatest area of unmet...
TESARO Announces Niraparib Data Presentations at the 2017 SGO Annual Meeting on Women’s Cancer
March 12, 2017 08:38 ET
|
TESARO, Inc.
WALTHAM, Mass., March 12, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced two niraparib presentations at the 2017 Society for...
TESARO Announces Fourth-Quarter 2016 Operating Results
February 28, 2017 16:05 ET
|
TESARO, Inc.
Niraparib NDA under review by FDA; pre-launch preparations for planned commercial launch well underwayExpanded access program (EAP) for niraparib open in U.S.; European EAP expected to open 1H...
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...